Sign In
Buy NNGPF
NN Group NV Earnings Calls
| Release date | Feb 12, 2026 |
| EPS estimate | $3.98 |
| EPS actual | $3.37 |
| EPS Surprise | -15.33% |
| Revenue estimate | 7.261B |
| Revenue actual | 6.805B |
| Revenue Surprise | -6.28% |
| Release date | Feb 18, 2026 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
| Release date | Aug 07, 2025 |
| EPS estimate | $3.93 |
| EPS actual | $0.86 |
| EPS Surprise | -78.04% |
| Revenue estimate | 9.539B |
| Revenue actual | 4.108B |
| Revenue Surprise | -56.94% |
| Release date | May 23, 2025 |
| EPS estimate | - |
| EPS actual | $0.80 |
| Revenue estimate | - |
| Revenue actual | 3.825B |
Last 4 Quarters for NN Group NV
Below you can see how NNGPF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | May 23, 2025 |
| Price on release | $60.32 |
| EPS estimate | - |
| EPS actual | $0.80 |
| Date | Price |
|---|---|
| May 19, 2025 | $62.68 |
| May 20, 2025 | $61.74 |
| May 21, 2025 | $61.74 |
| May 22, 2025 | $61.74 |
| May 23, 2025 | $60.32 |
| May 27, 2025 | $60.25 |
| May 28, 2025 | $60.32 |
| May 29, 2025 | $60.32 |
| May 30, 2025 | $60.32 |
| 4 days before | -3.76% |
| 4 days after | -0.0008% |
| On release day | 0% |
| Change in period | -3.76% |
| Release date | Aug 07, 2025 |
| Price on release | $67.65 |
| EPS estimate | $3.93 |
| EPS actual | $0.86 |
| EPS surprise | -78.04% |
| Date | Price |
|---|---|
| Aug 01, 2025 | $67.65 |
| Aug 04, 2025 | $67.65 |
| Aug 05, 2025 | $67.65 |
| Aug 06, 2025 | $67.65 |
| Aug 07, 2025 | $67.65 |
| Aug 08, 2025 | $67.65 |
| Aug 11, 2025 | $72.21 |
| Aug 12, 2025 | $72.21 |
| Aug 13, 2025 | $70.20 |
| 4 days before | 0% |
| 4 days after | 3.77% |
| On release day | 0% |
| Change in period | 3.77% |
| Release date | Feb 18, 2026 |
| Price on release | $81.18 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| Feb 11, 2026 | $82.39 |
| Feb 12, 2026 | $84.63 |
| Feb 13, 2026 | $81.48 |
| Feb 17, 2026 | $81.48 |
| Feb 18, 2026 | $81.18 |
| Feb 19, 2026 | $82.41 |
| Feb 20, 2026 | $82.41 |
| Feb 23, 2026 | $82.41 |
| Feb 24, 2026 | $82.23 |
| 4 days before | -1.47% |
| 4 days after | 1.29% |
| On release day | 1.52% |
| Change in period | -0.191% |
| Release date | Feb 12, 2026 |
| Price on release | $84.63 |
| EPS estimate | $3.98 |
| EPS actual | $3.37 |
| EPS surprise | -15.33% |
| Date | Price |
|---|---|
| Feb 06, 2026 | $80.50 |
| Feb 09, 2026 | $81.06 |
| Feb 10, 2026 | $81.06 |
| Feb 11, 2026 | $82.39 |
| Feb 12, 2026 | $84.63 |
| Feb 13, 2026 | $81.48 |
| Feb 17, 2026 | $81.48 |
| Feb 18, 2026 | $81.18 |
| Feb 19, 2026 | $82.41 |
| 4 days before | 5.13% |
| 4 days after | -2.63% |
| On release day | -3.72% |
| Change in period | 2.37% |
NN Group NV Earnings Call Transcript Summary of Q4 2025
NN Group reported strong FY2025 results, exceeding targets with operating capital generation (OCG) of EUR 2.1bn (vs target EUR 1.9bn), free cash flow slightly above the EUR 1.6bn target (up 7% YoY), and a strengthened Solvency II ratio of 220% (improved quality of capital). Growth segments performed well: Insurance Europe VNB +16% (multiyear average 12% AAGR), Japan VNB +25% (strong sales recovery after a product relaunch), and Netherlands Non-life gross written premiums +6% (P&C combined ratio 90.3%, overall Non-life combined ratio 92.9%). Digital and AI initiatives under the Future Ready program are already delivering benefits (236 AI use cases, 42% of sales from digital leads, and ~40% of the EUR 200m annual run-rate benefit target realized by end-2025). Management announced an enhanced capital-return package (+EUR 100m): EUR 50m incremental annual share buyback (now EUR 350m) and a EUR 50m step-up in dividend, producing a 13% year-on-year dividend per share increase to EUR 3.88. Guidance: flat reported OCG for 2026 (underlying business growth expected to offset non-structural '25 tailwinds) and continued confidence in meeting 2028 targets (OCG EUR 2.2bn, free cash flow > EUR 1.8bn). Capital framework remains: Solvency II comfort zone 150–200%, holding cash target EUR 0.5–1.5bn; with current solvency >200% the binding constraint for returns has moved to holding cash. Management emphasized disciplined M&A (opportunistic only) and continued focus on margin over volume in Non-life.
